Pfizer Stock Drops After Earnings. Guidance Fell Short of Estimates.

4 months ago 96
PR Distribution

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

Updated Feb. 8, 2022 8:26 am ET / Original Feb. 7, 2022 10:09 am ET

  • Order Reprints
  • Print Article

Pfizer now expects approximately $55 billion in combined revenues for its Covid-19 vaccine and antiviral in 2022, and what would be a record high overall revenue of between $98 billion and $102 billion.

Pfizer (ticker: PFE) reported full-year 2021 revenue of $81.3 billion early Tuesday, roughly in line with the FactSet consensus estimate of $81.8 billion, and full-year adjusted diluted earnings of $4.42 per share, above the FactSet consensus estimate of $4.41 per share.


Read Entire Article